Bleeding News and Research

RSS

Age-old practice of annual screening exams for cervical cancer may be harmful than helpful

For decades, women between the ages of 21 and 69 were advised to get annual screening exams for cervical cancer. In 2009, however, accumulating scientific evidence led major guideline groups to agree on a new recommendation that women be screened less frequently: every three years rather than annually.

10 Jul 2013

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A in children.

8 Jul 2013

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Baxter International Inc. today announced data featuring ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a leading recombinant treatment available worldwide, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands.

From Baxter International Inc. 5 Jul 2013

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen Idec nd Swedish Orphan Biovitrum AB (publ) presented new data that support the clinical and safety profile of their long-lasting recombinant factor VIII candidate ELOCTATE for hemophilia A.

4 Jul 2013

Expertly written, practical handbook of pediatric thrombosis and hemostasis

An expertly written, practical handbook for the clinical assessment and management of children with inherited or acquired bleeding and clotting disorders

4 Jul 2013

LARIAT procedure prevents stroke in patients who are unable to tolerate blood thinners

Jersey Shore University Medical Center is one of only a handful of hospitals in the country offering the recent FDA-approved LARIAT Suture Delivery Device procedure. Electrophysiologists and interventional cardiologists perform this innovative procedure to help prevent stroke in patients who suffer from atrial fibrillation and are unable to take blood thinners.

3 Jul 2013

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Biogen Idec and Swedish Orphan Biovitrum AB (publ) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis Congress in Amsterdam, The Netherlands.

3 Jul 2013

Researchers report that aerobic exercise can lessen or worsen ulcerative colitis symptoms

Aerobic exercise can lessen - or worsen - the symptoms of inflammatory bowel diseases such as ulcerative colitis, depending on the circumstances under which the exercise is undertaken, researchers report.

3 Jul 2013

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders.

2 Jul 2013

Study reports nearly half of facial cosmetic plastic surgery patients take herbal supplements

Preoperative evaluations before facial cosmetic surgery find that about half of patients are taking herbal and other supplements, reports a study in the July issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

2 Jul 2013

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.

2 Jul 2013

Study shows lymphatic circulatory system may be intimately involved in vascular disorders

The often forgotten lymphatic circulatory system may be intimately involved in vascular disorders, according to a study by researchers from The University of Texas Health Science Center at Houston (UTHealth) and University of Michigan. Their research was reported recently in the Proceedings of the National Academy of Sciences.

30 Jun 2013

Brisdelle receives FDA approval to treat hot flashes associated with menopause

The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.

29 Jun 2013

Study reports catheter ablation is more effective in preventing AFrecurrence

Using catheter ablation to create complete linear lesions around pulmonary veins, proved more effective than the creation of incomplete lesions in preventing recurrence of atrial fibrillation (AF), reports the GAP-AF study.

25 Jun 2013

Study finds decrease in risk of death from ischemic stroke in US black children

The excess risk of death from ischemic (due to reduced blood flow), but not hemorrhagic (due to bleeding), stroke in US black children has decreased over the past decade, according to a study by Laura L. Lehman, M.D., of Boston Children's Hospital, and colleagues.

25 Jun 2013

New study provides guidelines for stem cell transplantation in older MDS patients

A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes - the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia.

25 Jun 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

New model developed to predict atrial fibrillation stroke risk factors

A more accurate and reliable stroke prediction model has been developed to help physicians decide whether to start blood-thinning treatment for patients with atrial fibrillation, as described in the current online issue of the Journal of the American Heart Association.

21 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event is taking over-the-counter non-steroidal anti-inflammatory drugs, often to treat a musculoskeletal complaint.

13 Jun 2013

Bleeding News and Research

Age-old practice of annual screening exams for cervical cancer may be harmful than helpful

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Expertly written, practical handbook of pediatric thrombosis and hemostasis

LARIAT procedure prevents stroke in patients who are unable to tolerate blood thinners

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Researchers report that aerobic exercise can lessen or worsen ulcerative colitis symptoms

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Study reports nearly half of facial cosmetic plastic surgery patients take herbal supplements

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Study shows lymphatic circulatory system may be intimately involved in vascular disorders

Brisdelle receives FDA approval to treat hot flashes associated with menopause

Study reports catheter ablation is more effective in preventing AFrecurrence

Study finds decrease in risk of death from ischemic stroke in US black children

New study provides guidelines for stem cell transplantation in older MDS patients

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

New model developed to predict atrial fibrillation stroke risk factors

European Commission amends marketing authorisation for Celgene's REVLIMID

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News